NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

What is a warning for patients using carbonic anhydrase inhibitors for glaucoma?

1. May cause dizziness

2. Risk of sulfonamide allergy

3. High risk of infection

4. Potential for retinal detachment

The correct answer is: Risk of sulfonamide allergy

Carbonic anhydrase inhibitors, such as acetazolamide, are commonly used in the treatment of glaucoma. One important warning for patients using these medications is the risk of sulfonamide allergy. These medications contain a sulfonamide moiety, which can potentially lead to allergic reactions in some individuals who are sensitive to this class of drugs. It is crucial for healthcare providers to assess patients for any history of sulfonamide allergies before prescribing carbonic anhydrase inhibitors to avoid adverse reactions. Therefore, option B is the correct answer. Options A, C, and D are incorrect as they do not represent common warnings associated with carbonic anhydrase inhibitors in the treatment of glaucoma. While dizziness may be a side effect of some medications, it is not a prominent warning specifically associated with carbonic anhydrase inhibitors. High risk of infection and potential retinal detachment are also not typically listed as warnings for patients using carbonic anhydrase inhibitors for glaucoma.